Regulatory Tracker #1 (Sept 2026): FDA PCAC July 2026 & the 503A Bulks List

Byline: Momentum Editorial · As of: 2026-09-25 (ET)

Summary

As of 2026-09-25, the U.S. Food and Drug Administration (FDA) Pharmacy Compounding Advisory Committee (PCAC) was noticed and held materials for a July 23–24, 2026 public meeting on certain bulk drug substances nominated for the section 503A Bulks List (Federal Register notice 91 FR 20465, Document 2026-07361, Docket FDA-2025-N-6895). Day 1 agenda substance groups included BPC-157-related, KPV-related, TB-500-related, and MOTS-c / MOTs-C-related bulk drug substances (free base and acetate pairs as labeled by FDA). Day 2 covered Emideltide (DSIP)-related, Semax-related, and Epitalon-related bulk drug substances.

Committee vote tallies and yes/no outcomes for those substances remain UNKNOWN from primary FDA Event Materials as of this as-of date — this digest does not import trade-blog or law-firm “vote result” narratives as source of truth. PCAC recommendations are advisory and do not themselves amend 21 CFR 216.23; final inclusion or exclusion requires FDA rulemaking. This Tracker is regulator-notice literacy for documentation-minded researchers — not compounding-practice advice, not medical advice, and not a Momentum catalog claim.

How the 503A Bulks List works (plain English)

Section 503A of the Federal Food, Drug, and Cosmetic Act sets conditions under which certain human drug products compounded by a licensed pharmacist in a State-licensed pharmacy or Federal facility, or by a licensed physician, may qualify for specified exemptions from CGMP, adequate-directions labeling, and new-drug approval requirements (see FR notice Background citing 21 U.S.C. 353a and related sections).

One of those conditions concerns bulk drug substances used in compounding. In plain terms, when there is no applicable USP/NF monograph and the substance is not a component of an FDA-approved drug, the substance must appear on a list developed by the Secretary through regulations — commonly called the 503A Bulks List (see section 503A(b)(1)(A)(i); FR notice Background).

FDA has codified that list in 21 CFR Part 216, Subpart B, principally § 216.23. Substances FDA has included appear in § 216.23(a); substances considered and not included appear in § 216.23(b). Authority notes on eCFR cite the 2019 final rule publication (84 FR 4710, Feb. 19, 2019) for the current codified structure as described in FDA compounding materials.

PCAC’s role: The Pharmacy Compounding Advisory Committee provides advice and recommendations to FDA on regulatory issues. FDA’s own advisory-committee framing is that committee recommendations are not legally binding on the agency. A PCAC discussion or recommendation is not the same event as:

• publication of a final rule amending § 216.23;
• an interim “Category” placement change under FDA’s rolling 503A bulks evaluation policy; or
• a determination that any commercial research material is a compounded drug product.

Separately, FDA describes an interim policy for compounding using bulk drug substances under section 503A while evaluations continue. This Tracker cites those pages as process pointers only — it does not invent Category 1/2/3 table changes for July 2026 agenda substances (UNKNOWN without a fresh primary Category download).

July 23–24, 2026 PCAC: agenda substances & primary materials

Meeting notice (primary): Federal Register 91 FR 20465 (published 2026-04-16), Document 2026-07361, Docket FDA-2025-N-6895. Dates: July 23, 2026, 8:00 a.m.–4:30 p.m. ET; July 24, 2026, 8:00 a.m.–3:50 p.m. ET. Public docket for comments was established by that notice.

Day 1 — July 23, 2026 (substance groups named in the FR agenda)

Day 2 — July 24, 2026

Important framing wall: The “uses evaluated” column reproduces FDA’s review framing for the advisory committee meeting as published in the Federal Register notice. Those disease and condition strings are not Momentum Labs product claims, not research-use indications for any catalog SKU, and not dosing or treatment guidance.

Where to find primary materials

1. FDA Advisory Committee Calendar event page — July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee: fda.gov event page
2. Federal Register notice (HTML): federalregister.gov Doc 2026-07361
3. GovInfo HTML of the same notice: govinfo.gov FR-2026-04-16
4. Regulations.gov docket FDA-2025-N-6895: regulations.gov docket
5. FDA briefing introduction (example Event Material): fda.gov/media/193342
6. Final Agenda (example): fda.gov/media/193771
7. Day 1 FDA Presentations (example): fda.gov/media/193773
8. 2026 PCAC meeting materials index: 2026 PCAC materials index

Substance-specific FDA briefing PDFs on the Event Materials table should be cited by FDA.gov labels when opened. As of this digest’s as-of date, vote/minutes status rests on the absence of an FDA minutes/transcript URL among cited primary sources — not on third-party tallies.

What we can say about “the vote”

What the notice establishes: The July 2026 meeting was noticed for Committee discussion of the bulk drug substance groups listed above, with open public hearing time allotted by substance session on the FR Procedure section.

What remains UNKNOWN as of 2026-09-25 (do not invent):

Secondary sources (trade blogs, compounding newsletters, law-firm client alerts aggregating “vote results”) are excluded from source of truth. If FDA later posts minutes or a transcript PDF among Event Materials, cite that FDA URL + retrieval date — never third-party tallies alone.

Current codified list status (as of 2026-09-25)

Readers tracking “is substance X on the 503A Bulks List?” should start with the codified regulation, not meeting chatter.

Per the eCFR snapshot for 21 CFR § 216.23 (Subpart B) used for this digest as of 2026-09-25, and consistent with FDA’s compounding pages citing the 2019 final rule:

• § 216.23(a) — substances included on the 503A Bulks List (six topical / listed substances as codified): Brilliant Blue G; cantharidin topical; diphenylcyclopropenone topical; N-acetyl-D-glucosamine topical; squaric acid dibutyl ester topical; thymol iodide topical.
• § 216.23(b) — substances considered and not included (four as codified): oxitriptan; piracetam; Silver Protein Mild; tranilast.

None of the July 2026 agenda peptide-related substance groups appear on that § 216.23(a)/(b) snapshot as a newly added final-rule entry in the materials used for this digest. That is a statement about the codified list content as cited, not a prediction about future rulemaking.

Primary citation: eCFR — 21 CFR Part 216 Subpart B: ecfr.gov Part 216 Subpart B

Process pointers (not Category change claims):

• FDA — Bulk Drug Substances Used in Compounding Under Section 503A: fda.gov 503A bulks page
• FDA — Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (guidance landing): fda.gov interim policy guidance

Re-verification note: § 216.23 content in this digest follows the as-of 2026-09-25 primary-source snapshot cited above. If a later eCFR fetch shows a post-2019 amendment for agenda substances, update with that URL + date — do not invent changes.

How to track next steps

Practical watchlist (not legal advice; not “how to compound”):

1. FDA Event Materials / PCAC calendar — minutes, transcript, or vote-summary PDFs on the July 23–24, 2026 event page and 2026 PCAC materials index. Until posted, vote outcomes stay UNKNOWN.
2. Federal Register — proposed or final rules amending 21 CFR Part 216 / the 503A Bulks List. A PCAC recommendation is not a final rule.
3. Docket FDA-2025-N-6895 — related public filings on Regulations.gov.
4. FDA 503A bulks / interim-policy pages — when checking Category placement, verify the download date; do not invent table diffs.
5. Enforcement genres stay separate — warning letters and state actions are not advisory-committee agendas (regulator notices vs peer-reviewed). This edition asserts no warning-letter set for the July 2026 subjects.